https://mediamedic.co/study-led-by-dr-jianhong-zhong-explores-optimal-duration-of-adjuvant-immune-checkpoint-inhibitors-after-hepatectomy-in-high-risk-hcc/
Study Led by Dr. Jianhong Zhong Explores Optimal Duration of Adjuvant Immune Checkpoint Inhibitors...
Jun 13, 2025 - Background and Objective Hepatocellular carcinoma (HCC) is among the most common malignancies globally, with a high recurrence rate after resection, especially...
immune checkpoint inhibitorsjianhong zhongstudyleddr